Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 7/20 | 0.35 |
| ▸ | KDM1A | O60341 | 4/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | PDE2A | O00408 | 1/20 | 0.31 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.31 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2853663 | 0.91 | EPHX2 (0.35) | EPHX2KDM1ACTSKNAAAPDE2A | |
| SCHEMBL9013569 | 0.86 | EPHX2 (0.35) | EPHX2CTSKNAAAPDE2AHCRTR1 | |
| SCHEMBL9013573 | 0.86 | EPHX2 (0.35) | EPHX2CTSKNAAAPDE2AHCRTR1 | |
| SCHEMBL6461049 | 0.84 | EPHX2 (0.32) | EPHX2KDM1ACTSKNAAAP2RX7 | |
| SCHEMBL6461046 | 0.84 | EPHX2 (0.32) | EPHX2KDM1ACTSKNAAAP2RX7 | |
| SCHEMBL2845403 | 0.82 | HTR2A (0.37) | KDM1A | |
| SCHEMBL6455016 | 0.82 | KDM1A (0.34) | EPHX2KDM1ACTSKNAAAPDE2A | |
| SCHEMBL6455021 | 0.82 | KDM1A (0.34) | EPHX2KDM1ACTSKNAAAPDE2A | |
| SCHEMBL2852845 | 0.82 | KDM1A (0.39) | EPHX2KDM1A | |
| SCHEMBL5683741 | 0.80 | EPHX2 (0.30) | EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2010-10-21 | — | — | US | disclosed |
| EP-1896552-B1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON CHEMIE AG (LI) | 2010-05-19 | — | — | EP | disclosed |
| EP-1896552-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | Tetragon-Chemie AG (LI) | 2008-03-12 | — | — | EP | disclosed |
| WO-2006136345-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | TETRAGON-CHEMIE AG (LI) | 2006-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100264368-A1 | LIQUID CRYSTAL MOLECULES COMPRISING HYDROAZULENE STRUCTURES | FLI1, F12, GTF2I | EPHX2 975/4885KDM1A 3877/4885CTSK 4063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.